An analyst from Mizuho raised the price target for the healthcare services company from $400 to $413 and maintained an Outperform rating. The company expects to bring in over $50 billion in specialty revenue in fiscal 2026. However, over the past year, company insiders sold a significant stake worth $3.5 million, which may indicate hesitancy. The stock is also highlighted as one of the cheap S&P 500 stocks to invest in currently.